Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Niger has been steadily growing over the past few years.
Customer preferences: Niger has a relatively young population, with over 60% of its citizens under the age of 25. This demographic shift has led to an increase in cancer cases, particularly in breast, cervical, and prostate cancers. As a result, there is a growing demand for oncology drugs in the country.
Trends in the market: The market for oncology drugs in Niger is primarily driven by the government's efforts to improve cancer care in the country. The government has taken steps to increase the availability of cancer drugs and to improve cancer screening and diagnosis. This has led to an increase in the number of cancer patients seeking treatment, and consequently, an increase in demand for oncology drugs.
Local special circumstances: One of the major challenges facing the oncology drugs market in Niger is the lack of infrastructure and resources. Niger is one of the poorest countries in the world, and the healthcare system is severely underfunded. This has led to a shortage of medical personnel, equipment, and medicines, including oncology drugs. Additionally, there is a lack of awareness and education about cancer in the country, which has resulted in many cases being diagnosed at a late stage.
Underlying macroeconomic factors: Niger's economy is heavily dependent on agriculture, and the country has been facing recurring food crises due to droughts and floods. This has led to a high level of poverty and malnutrition, which in turn has contributed to an increase in the incidence of cancer. The government has been working to diversify the economy and reduce its dependence on agriculture, but progress has been slow. The country also faces security challenges, with the presence of terrorist groups in the northern and western regions. This has led to a reduction in foreign investment and a slowdown in economic growth. However, the government has remained committed to improving healthcare in the country, and this has led to some progress in the oncology drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
